$ORIC News

Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16

ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals Presents Multiple Poster Presentation At 2026 American Association For Cancer Research Annual Meeting On Potential Of Rinzimetostat For Prostate Cancer Treatment

A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data

Oric Pharmaceuticals shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $25 price target.

Oric Pharmaceuticals shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $25 price target.

ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3

HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

ORIC Pharmaceuticals: Updates Did Not Bode Well For This Valuation

What's Behind The Drop In Oric Pharmaceuticals Stock Today?

Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $17

Oric Pharmaceuticals shares are trading lower after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients with metastatic castration-resistant prostate cancer.

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Rinzimetostat Dose Optimization Data and Phase III Trial Design in Metastatic Prostate Cancer Transcript

ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?

Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial

ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile

ORIC Pharma Announces Efficacy And Safety Data From Phase 1b Trial Of Once Daily Rinzimetostat In Combination With Darolutamide In Patients With mCRPC Who Were Previously Treated With Abiraterone

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC